Alpha 1-antitrypsin deficiency surgery

Alpha 1-antitrypsin deficiency Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Alpha 1-antitrypsin deficiency from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications, and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Alpha 1-antitrypsin deficiency surgery On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Alpha 1-antitrypsin deficiency surgery All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Alpha 1-antitrypsin deficiency surgery
CDC on Alpha 1-antitrypsin deficiency surgery
Alpha 1-antitrypsin deficiency surgery in the news
Blogs on Alpha 1-antitrypsin deficiency surgery
Directions to Hospitals Treating Alpha 1-antitrypsin deficiency
Risk calculators and risk factors for Alpha 1-antitrypsin deficiency surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mazia Fatima, MBBS [2]

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

Lung Transplantation

• Lung transplantation may be recommended for some patients with end-stage lung disease.
• Alpha 1-antitrypsin deficiency accounts for about 5% of all lung transplantations performed in the United States.
• Single lung transplant is more common despite the fact that outcome is better in patient who receive double lung transplant due to limitations on availability.
• Five year survival rates following lung transplant is approximately 50%.
• Bronchiolitis obliterans being the major cause of death post-transplant.
• Outcomes of lung transplantation can vary considerably.
• For example, reports from Washington University Medical Center in St. Louis, the Copenhagen National Lung Transplant Group, and Zurich University Hospital reported no difference in 5-year survival rates between AATD-COPD and usual COPD recipients.
• In contrast, the Toronto group reported that AATD patients had lower 10-year survival (23% vs 43%) compared with usual COPD patients.
• A recent study from the 2 national lung transplantation centers in Sweden documented a median survival time for AATD-COPD patients of 12 years compared with only 6 years for usual COPD patients.
• The rate of FEV1 decline among AATD patients who received double lung transplantation was faster than among single lung recipients.
• This difference persisted after adjustment for age, smoking status, body mass index, oxygen use, exercise capacity, donor age, cytomegalovirus mismatch, and transplant type.
• The estimated median survival time was 11 years in transplant recipients versus 5 years in controls.

Lung Volume Reduction Surgery

• Lung volume reduction surgery (LVRS) can help relieve dyspnea and improve exercise capacity in patients with emphysema. Data regarding the efficacy of LVRS for individuals with AATD is limited and generally less favorable in magnitude and duration of FEV1 improvement.
• One study demonstrated that bilateral LVRS in AAT-deficient patients with emphysema can be beneficial but functional measurements except 6 min walk test, returned to baseline at 6–12 months. Although, LVRS was not recommended for management of AAT deficiency.

References

Template:WikiDoc Sources